liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
No induction of thiopurine methyltransferase during thiopurine treatment in inflammatory bowel disease
Linköping University, Faculty of Health Sciences. Linköping University, Department of Medicine and Care, Clinical Pharmacology.ORCID iD: 0000-0002-2809-7591
Linköping University, Faculty of Health Sciences. Linköping University, Department of Molecular and Clinical Medicine, Gastroenterology and Hepatology. Östergötlands Läns Landsting, Centre for Medicine, Department of Endocrinology and Gastroenterology UHL.
Linköping University, Faculty of Health Sciences. Linköping University, Department of Biomedicine and Surgery, Division of cell biology.
Show others and affiliations
2006 (English)In: Nucleosides, Nucleotides & Nucleic Acids, ISSN 1525-7770, E-ISSN 1532-2335, Vol. 25, no 9-11, 1033-1037 p.Article in journal (Refereed) Published
Abstract [en]

The aim of this study was to follow, during standardized initiation of thiopurine treatment, thiopurine methyltransferase (TPMT) gene expression and enzyme activity and thiopurine metabolite concentrations, and to study the role of TPMT and ITPA 94C > A polymorphisms for the development of adverse drug reactions. Sixty patients with ulcerative colitis or Crohn's disease were included in this open and prospective multi-center study. Thiopurine naïve patients were prescribed azathioprine (AZA), patients previously intolerant to AZA received 6-mercaptopurine (6-MP). The patients followed a predetermined dose escalation schedule, reaching target dose at Week 3, 2.5 and 1.25 mg/kg body weight for AZA and 6-MP, respectively. The patients were followed every week during Weeks 1-8 from baseline and then every 4 weeks until 20 weeks. TPMT activity and thiopurine metabolites were determined in erythrocytes, TPMT and ITPA genotypes, and TPMT gene expression were determined in whole blood. One homozygous TPMT-deficient patient was excluded. Five non compliant patients were withdrawn during the first weeks. Twenty-seven patients completed the study per protocol, 27 patients were withdrawn because of adverse events. Sixty-seven percent of the withdrawn patients tolerated thiopurines at a lower dose at Week 20. There was no difference in baseline TPMT enzyme activity between individuals completing the study and those withdrawn for adverse events (p = 0.45). A significant decrease in TPMT gene expression (TPMT/huCYC ratio, p = 0.02) was found, however TPMT enzyme activity did not change. TPMT heterozygous individuals had a lower probability of remaining in the study on the predetermined dose (p = 0.039). The ITPA 94C > A polymorphism was not predictive of adverse events (p = 0.35). Copyright © Taylor & Francis Group, LLC.

Place, publisher, year, edition, pages
2006. Vol. 25, no 9-11, 1033-1037 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-35538DOI: 10.1080/15257770600890814Local ID: 27508OAI: diva2:256386
Available from: 2009-10-10 Created: 2009-10-10 Last updated: 2013-09-03

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Lindqvist Appell, MalinAlmer, SvenSöderkvist, PeterStröm, MagnusHjortswang, HenrikPeterson, Curt
By organisation
Faculty of Health SciencesClinical PharmacologyGastroenterology and HepatologyDepartment of Endocrinology and Gastroenterology UHLDivision of cell biologyDepartment of Clinical Pharmacology
In the same journal
Nucleosides, Nucleotides & Nucleic Acids
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 36 hits
ReferencesLink to record
Permanent link

Direct link